PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|May 2, 2022
- Pharmaceutical Technology, May 2022
- Volume 46
- Issue 5
- Pages: 48–51
Weighing Isn’t an Uncertain Process, Is It?
Author(s)Christopher Burgess
This article provides best practice to avoid errors in weighing by difference caused by buoyancy and drift.
Advertisement
Weighing samples and standards is a fundamental analytical operation. It is such a familiar laboratory operation, usually digitally displayed and captured, that one tends to intuitively believe that the numbers from balances are error free, or at least have such a small uncertainty that any errors will be negligible. On many occasions, this may well be true but not always. Modern electronic balances rely on a load cell. As force is applied to the loadcell or transducer by calibrated masses, the response is measured. The responses from the loadcell are transformed into a mass calibration function supported by digital averaging, smoothing, and rounding firmware, which leads to the displayed mass on the balance. The purpose of this article is to look at the uncertainties in terms of their source, and provide one best practice to avoid errors in weighing by difference caused by buoyancy and drift.
About the author
Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.
Article details
Pharmaceutical Technology
Volume 46, Number 5
May 2022
Pages: 48–51
Citation
When referring to this article, please cite it as C. Burgess, "Weighing Isn’t an Uncertain Process, Is It?," Pharmaceutical Technology 46 (5) (2022).
Articles in this issue
over 4 years ago
Speeding Up Development for Traditional Biologicsover 4 years ago
Inhalation Formulation Development: Predicting API Behaviorover 4 years ago
An Evolving Approach to Drug Deliveryover 4 years ago
Topical Formulations in Pharma–Balancing Form and Functionover 4 years ago
Assessing the Success of CRISPR Gene Therapies Using ddPCRover 4 years ago
A Robust Quality Culture Benefits Allover 4 years ago
Advances in Dissolution TestingAdvertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement